Metabolic Syndrome Screening in Seriously Mentally Ill Patients: A Quality Improvement Project

Abstract

Seriously mentally ill patients who are taking second-generation antipsychotics have a high risk of metabolic complications, including obesity, diabetes mellitus type II, hypertension, and hyperlipidemia. Guidelines to screen for metabolic syndrome were established by the American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity (Clark, 2004). Compliance with implementing the guidelines to screen and monitor for metabolic syndrome vary from regular monitoring to little or none. This quality improvement project provided an educational intervention on screening and monitoring for metabolic syndrome in patients who were seriously mentally ill. The educational interventions were attended by 21 psychiatric-mental health nurse practitioners. After the educational intervention was completed, there was significant improvement in provider knowledge as well as motivation to screen and monitor patients taking second-generation antipsychotic medications for metabolic syndrome. Education may motivate mental health providers to increase the use of metabolic screening guidelines for patients taking second-generation antipsychotic medications potentially improving long term outcomes for this patient population.